Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
January 23, 2023 at 08:37 pm IST
Share
Syngene International Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 7,859 million compared to INR 6,414 million a year ago. Revenue was INR 8,031 million compared to INR 6,543 million a year ago. Net income was INR 1,097 million compared to INR 1,040 million a year ago. Basic earnings per share from continuing operations was INR 2.74 compared to INR 2.57 a year ago. Diluted earnings per share from continuing operations was INR 2.71 compared to INR 2.55 a year ago.
For the nine months, sales was INR 21,985 million compared to INR 18,461 million a year ago. Revenue was INR 22,466 million compared to INR 18,842 million a year ago. Net income was INR 2,856 million compared to INR 2,480 million a year ago. Basic earnings per share from continuing operations was INR 7.12 compared to INR 6.12 a year ago. Diluted earnings per share from continuing operations was INR 7.06 compared to INR 6.08 a year ago.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.